Safety of Celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and other non-steroidal anti-inflammatory drugs

Journal of Investigational Allergology and Clinical Immunology

Volumn 15, Issue 4, 2005, Pages 249-253

  Liccardi, G ^a   Cazzola, M ^a   De Giglio, C ^a   Manfredi, D ^a   Piscitelli, E ^a   D'Amato, M ^a   D'Amato, G ^a  

^a CARDARELLI HOSPITAL   (Italy)

Author keywords

Celecoxib; Cutaneous adverse reactions; Drug allergy; NSAIDs; Paracetamol

Indexed keywords

ACETYLSALICYLIC ACID; ACICLOVIR; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; BETA LACTAM; CELECOXIB; CETIRIZINE; DICLOFENAC; DIPYRONE; KETOROLAC; MACROLIDE; METHYLPREDNISOLONE; MORNIFLUMATE; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OXICAM DERIVATIVE; PARACETAMOL;

ADOLESCENT; ADULT; ANGIONEUROTIC EDEMA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; HUMAN; HYPERSENSITIVITY REACTION; IN VIVO STUDY; LIP DISEASE; MALE; PATIENT; PROVOCATION TEST; PRURITUS; SINGLE BLIND PROCEDURE; SKIN MANIFESTATION; URTICARIA;

ACETAMINOPHEN; ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; MALE; MIDDLE AGED; PYRAZOLES; SINGLE-BLIND METHOD; SKIN DISEASES; SULFONAMIDES;

EID: 33244487220     PISSN: 10189068     EISSN: 16980808     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Mitchell JA, Warner TD. Cyclo-oxygenase. Pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br J Pharmacol 1999;128:1121-32.
2. Szczeklik A, Sanak M. The role of COX-1 and COX-2 in asthma pathogenesis and its significance in the use of selective inhibitors. Clin Exp Allergy 2002;32:339-42.
3. Vane J. Aspirin and other anti-inflammatory drugs. Thorax 2000;55(Suppl 2): S3-S9.
4. Szczeklik A. Analgesics, allergy and asthma. Drugs 1986;32:148-63.
5. Settipane RA, Schrank PJ, Simon RA, Mathison DA, Christiansen SC, Stevenson DD. Prevalence of cross reactivity with acetaminophen in aspirin-sensitive asthmatic subjects. J Allergy Clin Immunol 1995;96:480-85
6. Ayonrinde OT, Saker BM. Anaphylactoid reactions to paracetamol. Postgrad Med J 2000;76:501-02.
7. Ibanez MD, Alonso E, Munoz MC, Martinez E, Laso MT. Delayed hypersensitivity reaction to paracetamol (acetaminophen). Allergy 1996;51:121-23.
8. Moneret -Vautrin DA, Morisset M, Humbert JC, Beaudonin E, Tupin N, Plantier L. Acetaminophen-induced rhabdomyolysis. Allergy 1999;54:1115-16.
9. Fitzgerald GA, Patrono C. The coxibs, selective inhibitors of cyclo-oxigenase -2. N Engl J Med 2001;345:433-42.
10. Clemett D, Goa KL. Celecoxib : a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs 2000;59:957-80.
11. Patterson R, Bello AE, Lefkowith J. Immunologic tolerability profile of celecoxib. Clin Ther 1999;21:2065-79.
12. Garcia-Rodriguez RM, Hinojose M, Camacho-Garrido E, Berges-Gimeno P, Martin Garcia C. Celecoxib is safe in NSAID intolerance. Allergy 2002;57:1085-86.
13. Dahlen B, Szczeklik A, Murray JJ. Celecoxib in patients with asthma and aspirin intolerance. N Engl J Med 2001;344:142.
14. Ortolani C, D'Amato G, Giannetti A, Marone G, Moscato G, Meneghini A. Memorandum SIAIC nella diagnosi di allergia/ intolleranza ai farmaci. Giornit Allergol Clin Immunol 1998;8:568-95.
15. Dreborg S, Frew A. Position Paper. Allergen standardization and skin tests. Allergy 1993;48(Suppl 14):49-83.
16. Hubky R, Vermeulen C, Bachmeyer C, Charoud A, Mofredi A. Anaphylactic shock induced by celecoxib. Ann Int Med 2001;152:355.
17. Levy MB, Fink JN. Anaphylaxis to celecoxib. Ann Allergy asthma Immunol 2001;87:72-73.
18. Gagnon R, Julien M, Gold P. Selective celecoxib-associated anaphylactoid reaction. J Allergy Clin Immunol 2003;111:1404-05.
19. Szczeklik A, Nizankowska E, Bochenek G, Nargraba K, Mejza F, Swierczynska M. Safety of a specific COX-2 inhibitor in aspirin-induced asthma. Clin Exp Allergy 2001;31:219-25.
20. Martin Garcia C, Hinojosa M, Berges P, Camacho-Garrido E, Garcia Rodriguez RG, Alfaya T, Iscar A. Safety of a cyclo-oxygenase-2 inhibitor in patients with aspirin-sensitive asthma. Chest 2002;121:1812-17.
21. Zembowicz A, Mastalerz L, Setkowicz M, Radziszewski W, Szczeklik A. Safety of cyclo-oxygenase-2 inhibitors and increased leukotriene synthesis in chronic idiopathic urticaria with sensitivity to non steroidal anti-inflammatory drugs. Arch Dermatol 2003;139:1577-82.
22. Pacor ML, Di Lorenzo G, Biasi D, Barbagallo M, Corrocher R. Safety of rofecoxib in subjects with a history of adverse cutaneous reactions to aspirin and/or non-steroidal antiinflammatory drugs. Clin Exp Allergy 2002;32:397-400.
23. Asero R. Tolerability of rofecoxib. Allergy 2001;56:916-17.
24. Nettis E, Di Paola R, Ferranini A, Tursi A. Tolerability of rofecoxib in patients with cutaneous adverse reactions to non-steroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2002;88:331-34.
25. Perrone MR, Artesani MC, Viola M, Gaeta F, Caringi M, Quaratino D, Romano A. Tolerability of rofecoxib in patients with adverse reactions to non-steroidal anti-inflammatory drugs: a study of 216 patients and literature review. Int Arch Allergy Immunol 2003;132:82-86.
26. Kvedariene V, Bencherioua AM, Messaad D, Godard P, Bousquet J, Demoly P. The accuracy of the diagnosis of suspected paracetamol (acetaminophen) hypersensitivity: results of a single -blinded trial. Clin Exp Allergy 2002;32:1366-69.
27. Topol EJ, Falk GW. A coxib a day won't keep the doctor away. Lancet 2004;364:639-40.
28. Mukherjee D, Nissen S, Topol EJ. Risk of cardio vascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-59.
29. Bogaty P, Brophy JM, Noel M, Boyer L, Simard S, Bertrand F, Dagenais GR. Impact of prolonged cyclo-oxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C - reactive protein. A randomized placebo-controlled study. Circulation 2004;110:934-39.